RxDoctor Payments Data

Najam Sheikh, MD

Neurodevelopmental Disabilities · South Williamson, KYNPI 1437394681

Payments from drug & device makers

$2,494in general payments, 2019–2025

Across 61 payments — averaging $40.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • AbbVie$455
  • Lilly USA, LLC$108
  • Johnson & Johnson$103
  • Novartis$75
  • Amgen$71
  • plus $326 from 13 others

What the payments were for

  • Travel & lodging$92037%
  • Food & beverage$1,57363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurodevelopmental disabilities providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$12,223
Medicare patients
60
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValtocoDiazepam12$8,334
Gabapentin493$4,877
Levetiracetam114$1,803
Memantine Hcl ErMemantine Hcl23$1,751
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$1,689
Carbidopa-LevodopaCarbidopa/Levodopa116$1,265
Carbamazepine60$1,143
Lamotrigine77$792
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine30$480
Phenytoin Sodium Extended17$363
Diclofenac Sodium25$297
Acetazolamide12$236
Topiramate25$225
Baclofen31$163
Primidone20$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurelis, Inc.Valtoco$23$8,33412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurodevelopmental disabilities providers in Kentuckyon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →